59 results about "Antiserum" patented technology

Provided are methods of treating liver diseases comprising administering recombinant proteins comprising an interleukin-18-binding protein and an antigen binding fragment that binds to serum albumin.

The invention discloses a duck BRS3 polypeptide and a preparation method and application of a polyclonal antibody of the duck BRS3 polypeptide, and belongs to the field of biochemistry and molecular immunology. The amino acid sequence of the duck BRS3 polypeptide is as shown in SEQ ID NO. 3. A segment of polypeptide sequence with the length of 20 aa is screened out in an intracellular region of a duck BRS3 protein sequence, after artificial solid-phase synthesis, the polypeptide sequence is used as an immunizing antigen to immunize New Zealand white rabbits, and the duck BRS3 protein polyclonal antibody with the antiserum titer being 1: 25600 or above is obtained. The rabbit anti-duck BRS3 polyclonal antibody prepared by the invention can be specifically combined with the BRS3 protein in duck tissues, so that the blank in the field of detection and research of the duck BRS3 protein is filled, and a foundation is laid for research of functions of the BRS3 in duck bodies.

The invention belongs to the field of biology, and discloses an mRNA (messenger ribonucleic acid) with a nucleotide sequence as shown in SEQ ID NO.3. Antiserum of a strain (A / chick / Gansuu / 28 / 2024) corresponding to the mRNA has relatively good reactivity with other strains and poorer reaction with a current vaccine strain RE-13, the branched strain is a current epidemic strain, and the mRNA prepared from the HA gene of the strain has the advantage of strong protection; the invention also aims to provide the mRNA, application thereof and a vaccine.

The application belongs to the technical field of biotechnology, and particularly relates to a human metapneumovirus mouse-adapted strain and application thereof. Compared with wild strains, the strain can exhibit stronger susceptibility to animals, and can cause typical clinical symptoms and even death. For example, after the strain infects BALB / c mice, the disease symptoms are obvious, 83% of the mice have a severe decrease in body weight to below 75% after infection, and have reached the humane killing standard. Four days after the strain infects BALB / c mice, the mortality rate is above 50%. The strain can be used to construct a cell model or an animal model of human metapneumovirus infection or a disease caused by the human metapneumovirus, and is further used to screen drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus. In addition, the strain can also be used to prepare drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus, and to prepare antibodies or antisera against the human metapneumovirus.

The invention relates to the technical field of biological medicines, and discloses a construction method and expression application of an Hcp gene deleted strain of a rahnella aqua KCL-5 strain for fish. The Hcp 0186 gene deletion strain is constructed by using a homologous recombination method, the comparison between the deletion strain and a wild strain is carried out, and the result shows that the deletion of the Hcp 0186 gene has an influence on the growth speed, the pathogenicity of the Hcp 0186 gene to the zebra fish is obviously reduced, the survival rate of the infected zebra fish is increased from 0% to 52%, and the Hcp 0186 gene deletion strain can be used as a fish attenuated live vaccine. A recombinant prokaryotic expression vector pET32a-Hcp and expression and purification of fusion protein of the recombinant prokaryotic expression vector pET32a-Hcp are further constructed, and Hcp 0186 rabbit polyclonal antibody serum is prepared as a primary antibody and can be applied to localization expression analysis of fish tissues infected by the bacterium and detection of WB and IHC. Results prove that the Hcp 0186 gene deletion of the strain provides an attenuated strain vaccine and clinical diagnosis and detection application of infected fish of the attenuated strain vaccine, and a scientific basis can be provided for revealing a molecular pathogenic mechanism of the strain and development and application of a mutant strain of the strain.

The invention discloses a crassostrea hongkongensis NKA-alpha protein polyclonal antibody as well as a preparation method and application thereof. The preparation method comprises the following steps: constructing a recombinant expression vector containing an NKA-alpha target gene segment; transforming the recombinant expression vector into competent cells to construct a recombinant expression strain, inducing the recombinant expression strain to express fusion protein, and collecting and purifying to obtain NKA-alpha recombinant protein; carrying out animal immune treatment by taking the NKA-alpha recombinant protein as an antigen, collecting and separating antiserum, and purifying to obtain the Crassostrea hongkongensis NKA-alpha protein polyclonal antibody. The prepared Crassostrea hongkongensis NKA-alpha polyclonal antibody is high in affinity, can specifically recognize NKA-alpha protein in Crassostrea hongkongensis, and can be widely applied to Crassostrea hongkongensis biological immunodetection.

The invention discloses a preparation method and application of carassius auratus rahn aquatic OmpA gene cloning and prokaryotic expression as well as a polyclonal antibody. The preparation method comprises the following steps: culture and DNA amplification of rahn aquatic, design of an OmpA primer, gene cloning and prokaryotic expression, back multi-point subcutaneous injection of an immune rabbit, heart blood sampling and preparation of the polyclonal antibody. The invention further provides OmpA protein prokaryotic expression and protein purification, preparation of OmpA polyclonal antiserum and application of fish bodies. According to the invention, a rahnella aquatilis OmpA gene is cloned, a specific Hind III and EcoR1 double-enzyme digestion primer sequence OmpA-1F / OmpA-1R is designed, a prokaryotic expression vector pET32a-OmpA is constructed, high-immunogenicity OmpA protein is obtained through purification, OmpA specific multi-antibody serum is prepared, and the OmpA specific multi-antibody serum can be used for preparing the multi-antibody serum. The OmpA polyclonal antibody can be used for detecting and positioning the expression application of rahnella aquatica OmpA protein in crucian carp bodies through bidirectional agar diffusion, an immunoblotting method and an immunohistochemical method, and provides a reference basis for research and development and application of rahnella aquatica subunit vaccines and a molecular diagnosis technology as well as immune prevention and control of infectious diseases of the rahnella aquatica subunit vaccines and the molecular diagnosis technology.

The invention relates to key antigen epitope screening, in particular to an echovirus 18 type key antigen epitope peptide and application thereof. The result of an enzyme-linked immunosorbent assay shows that Epitope 1 (SEQ ID NO: 1) can be effectively combined with E18-VP1 antiserum, and the combining capacity is obviously higher than that of Epitope 2 in a blank control and a negative result, so that one antigen epitope peptide is screened based on the complete sequence of the echovirus 18-VP1, and the antigen epitope peptide has important guiding significance for research and development of echovirus 18 vaccines.

This invention relates to a high-titer prealbumin antibody purification method and its application, belonging to the field of biotechnology. The method utilizes Protein A affinity chromatography to capture total IgG from antiserum, followed by purification using an affinity chromatography column prepared by targeted conjugation of a specific sequence peptide. The antibody purified by this method achieves a titer of 1:256,000 in ELISA detection, with a half-maximal effective concentration (EC50). 50 The antibody concentration was 3.2 ng / mL, exhibiting extremely high affinity and reactivity. When used in a double-antibody sandwich chemiluminescent immunoassay, it achieved a detection limit of 0.08 µg / mL, a wide dynamic range (0.08–400 µg / mL), and a titer retention rate as high as 88% after accelerated storage at 37°C for 14 days, demonstrating significantly better stability than antibodies prepared by traditional methods. This invention provides a highly active and stable core antibody raw material for the preparation of high-performance immunodiagnostic reagents.

The application provides a non-pH-dependent long-acting anti-serum albumin nanobody and an application thereof. Specifically, the application provides amino acid sequences of VHH chain framework regions FR and complementarity determining regions CDR of the non-pH-dependent long-acting anti-serum albumin nanobody. The application also provides nucleotide sequences encoding the nanobody. The anti-serum albumin nanobody provided by the application can bind to human, mouse, rat and cynomolgus serum albumin under different pH conditions, and can significantly prolong the half-life of a protein drug, thereby providing a research basis for long-acting protein drug development.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

The invention discloses a duck GRPR polypeptide and a preparation method and application of a polyclonal antibody of the duck GRPR polypeptide, and belongs to the field of biochemistry and molecular immunology. The duck GRPR gene is cloned for the first time, and the structure of the duck GRPR gene is analyzed; the preparation method comprises the following steps: taking amino acid polypeptide at 350-368 sites of a carboxyl terminal of duck GRPR protein as a hapten, and carrying out N-terminal modification on a polypeptide sequence to obtain duck GRPR modified polypeptide; and coupling the modified polypeptide with a carrier protein keyhole limpet hemocyanin to prepare a complete antigen, immunizing an animal, and separating and purifying from antiserum to obtain the polyclonal antibody of the duck GRPR polypeptide. Experiments show that the polyclonal antibody can be specifically combined with GRPR protein in duck tissue. According to the invention, the blank in the field of duck GRPR protein detection and research is filled, and a foundation is laid for research of the functions of the GRPR in the duck body.

The application discloses an anti-serum albumin nanobody 3A12 and long-acting application thereof, and belongs to the technical field of antibody engineering. The nanobody complementarity determining region comprises CDR-H1 shown in SEQ ID NO. 2 (SGYIA), CDR-H2 shown in SEQ ID NO. 3 (GIYRLGSSTFYADSVKG), and CDR-H3 shown in SEQ ID NO. 4 (GSTDRSLLRKPDTFNY). The nanobody is coupled with a therapeutic polypeptide, protein or antibody drug to construct a long-acting complex. The complex can significantly delay the renal clearance rate of the drug, resist protease degradation, increase the half-life of the drug, thereby avoiding frequent administration, maintaining the curative effect while reducing the administration frequency, and improving the patient compliance and treatment safety. The application is particularly suitable for the development of long-acting polypeptide, protein and antibody drugs.

The invention relates to the technical field of biology, in particular to antigen polypeptide of mandulapalka functional centromere histone CENH3 and application of the antigen polypeptide. The amino acid sequence of the antigen polypeptide is shown as SEQ ID No: 3. The polypeptide is used for conventionally immunizing New Zealand white rabbits to prepare antiserum and an anti-CENH3 protein antibody subjected to antigen affinity purification. The verification proves that the antibody is effective and reliable, and the functional centromere of the cyperus esculentus can be accurately identified. The method has a wide application prospect in the research fields of molecular cytogenetics, genomics, epimics and the like of cyperus esculentus.

The invention belongs to the technical field of biological medicines, and particularly relates to a human NSUN2 protein 190th lysine site lactic acid antigen, an antibody, a preparation method and application thereof. Relates to the technical field of lactylated antibody preparation, and the preparation method comprises the following steps: S01, carrying out lactylation on 190th lysine in a polypeptide of an amino acid sequence, and coupling with a carrier protein to obtain an initial antigen, the carrier protein comprising hemocyanin KLH; s02, injecting the obtained antigen into a living body culture sample for immune culture, and collecting whole blood after a preset period to obtain multi-antibody serum; and S03, purifying to obtain an iterative antibody. According to the invention, the expression difference in sensitive and drug-resistant tumor cells and tumor tissues can be detected by directly applying Western Blotting, immunofluorescence and immunohistochemistry, so that a powerful guarantee is provided for the detection of tumor sensitivity.

The present invention relates to anti-serum albumin antibodies and multispecific binding proteins comprising the same. The present invention also relates to pharmaceutical compositions comprising the antibodies or multispecific binding proteins, expression vectors and host cells for making the antibodies or multispecific binding proteins, and methods of using the antibodies or multispecific binding proteins for treating diseases or conditions.

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

The present invention discloses a specific antibody for acetylation at the CDC42-K153 site, a preparation method and an application thereof, and relates to the field of biotechnology. The amino acid sequence of the antibody is shown in SEQ ID NO: 1; the preparation method thereof is as follows: a CDC42-K153 peptide segment DLKAVKYVECSALTQKGL is prepared by a synthetic method, and the nucleotide sequence thereof is shown in SEQ ID NO: 2; and an acetylated modified peptide segment is obtained, and a peptide segment without an acetylated group is used as a control peptide segment. The acetylated modified peptide segment is immunized with New Zealand white rabbits to produce a site-specific acetylated polyclonal antibody and obtain an antiserum; the application of the specific antibody for acetylation at the K153 site in determining the expression level of acetylation at K153 of CDC42. The present invention develops a specific antibody for acetylation at the K153 site, which is applied to the determination of acetylated antigens at the K153 site of the CDC42 protein, and has good specificity and sensitivity.

This invention relates to the field of biochemical technology, and particularly to highly specific haptens of polymyxin B and colistin, artificial antigens, their preparation methods, and applications. The haptens have structures as shown in Formula I or Formula II. The applications include: (1) preparing specific antibodies against polymyxin B or colistin; (2) detecting specific antibodies against polymyxin B or colistin; and (3) preparing reagents for detecting specific antibodies against polymyxin B or colistin. This invention further provides artificial antigens obtained by conjugating the haptens with carrier proteins. Using the artificial antigens provided by this invention as immunogens to immunize experimental animals, highly specific and sensitive antiserum can be prepared, which can then be used to extract and prepare polyclonal antibodies. These methods can be used to establish highly specific, highly sensitive, simple, and rapid detection methods for polymyxin B and colistin, and have significant application value.

The application relates to the technical field of medical devices, and discloses a protein analysis device for HbA1C antiserum buffer, which comprises an analysis machine main body and a bar code input mechanism installed in the inner cavity of the analysis machine main body, and further comprises: a mounting frame installed on one side of the inner cavity of the analysis machine main body and corresponding to the position of the bar code input mechanism; an electric telescopic rod installed in the interior of the analysis machine main body and corresponding to the position of the bar code input mechanism; and a dismounting assembly arranged on the output shaft of the electric telescopic rod. The space posture of a test tube is adjusted in real time through the cooperative driving of the electric telescopic rod, a micro motor and a rotating roller, so that the surface label of the test tube and the scanning area of the bar code input mechanism are accurately aligned. The foreign matters on the test tube and the surface label can be effectively removed, and the raised label edge can be physically smoothed. The auxiliary mechanism can be regularly cleaned and disinfected through the linkage mechanism of the electric telescopic rod and the cleaning mechanism.

The present invention relates to a nanobody or antigen-binding fragment thereof that specifically binds to serum albumin, a derivative comprising the nanobody or the antigen-binding fragment thereof, a nucleic acid encoding the antibody or antigen-binding fragment thereof, a host cell comprising same, and related uses. Further, the present invention relates to therapeutic use of the antibody or the antigen-binding fragment thereof or the derivative.

The invention relates to the technical field of biological medicine, in particular to a cupreuloplasmin detection kit and a preparation method thereof, the kit comprises a reagent R1 and a reagent R2; the reagent R1 is prepared from a tris (hydroxymethyl) aminomethane buffer solution, polyethylene glycol-8000, sodium azide, tween-80 and magnesium acetate; the reagent R2 is prepared from a trihydroxymethyl aminomethane buffer solution, tween-20, sodium azide, goat anti-human copper cyanin antiserum, bovine serum albumin and L-proline. According to the invention, the gradient surfactant design and the metal ion auxiliary antigen conformation stability are introduced, so that the detection sensitivity and the anti-interference capability are synergistically improved; by constructing a ternary antibody stabilization system, the long-term stability of the reagent is remarkably enhanced, and the batch-to-batch difference is reduced. The kit has the advantages of high sensitivity, strong specificity, good stability and batch-to-batch consistency.

The invention relates to a multivalent vaccine, in particular to a chimera multivalent vaccine based on Ercovirus type 11, 18 and 30 key epitopes as well as a preparation method and application of the chimera multivalent vaccine. According to the invention, a chimera multivalent vaccine VP1-III is also designed based on key epitopes, an E11-VP1 sequence is taken as a basis, one E18-VP1 key epitope and two E30-VP1 key epitopes are respectively inserted into the E11-VP1 sequence to obtain a chimera multivalent protein vaccine VP1-III, and the chimera multivalent protein vaccine VP1-III is taken as an immunogen to immunize a mouse to detect antibody titer and virus neutralizing capacity of antiserum. A new thought is provided for designing and preparing multivalent vaccines and detecting immunogenicity of viral vaccines.

The invention discloses a duck NMBR polypeptide, a polyclonal antibody and application, and belongs to the field of biochemistry and molecular immunology. The duck NMBR gene is cloned for the first time, and the structure of the duck NMBR gene is analyzed; amino acids at 341-359 sites at the carboxyl terminal of duck NMBR protein are used as haptens, the haptens are coupled with keyhole limpet hemocyanin to prepare complete antigens, then animals are immunized, and the polyclonal antibody of the duck NMBR polypeptide is separated and purified from antiserum. Experiments show that the polyclonal antibody can specifically bind to NMBR protein in duck tissue. According to the invention, the blank in the field of duck NMBR protein detection and research is filled, and a foundation is laid for research of the function of the NMBR in the duck body.

The present application proposes a human cytomegalovirus UL135 protein antibody and its preparation method and application, which relate to the field of immune prevention and treatment technology. The preparation method is: according to the sequence of the human cytomegalovirus UL135 gene, an antigenic epitope is selected, and the gene sequence of the antigenic epitope is shown in SEQ ID NO.1; the antigenic epitope polypeptide is synthesized in solid phase using the above antigenic epitope and purified; the above antigenic epitope polypeptide is immunized in animals to produce human cytomegalovirus UL135 antiserum; the above human cytomegalovirus UL135 antiserum is purified to obtain a specific UL135 protein antibody. The present application develops an HCMV tissue detection antibody based on the HMCV latent infection-related protein UL135, and the protein antibody can be used for the detection of latent HCMV infection in tumor tissue. It has the advantages of high operational sensitivity and high specificity, and is suitable for clinical immunohistochemistry detection.

This invention relates to the field of bioengineering technology, specifically to a method for preparing neutrophil gelatinase-associated lipid transport protein and its antibody. Specifically, using pET23a(+) as the expression vector, the NGAL gene with six His tags fused to its N-terminus under promoter control is introduced into *E. coli* for induced expression. After purification using a Ni Focurose 6FF column and a molecular sieve column, tag-free NGAL protein with a purity ≥95% is obtained. Subsequently, the NGAL protein is used to repeatedly immunize Japanese rabbits, and serum is collected after each immunization. Qualified serum is screened using a two-dimensional agar diffusion assay, and then purified using the aforementioned antigen to prepare an antigen affinity purification column, yielding a highly active NGAL polyclonal antibody. The high-purity recombinant NGAL of this invention not only possesses activity but is also low-cost, not limited by raw materials, and can be mass-produced, possessing potential and wide-ranging application value in clinical and in vitro diagnostics.

The invention relates to the technical field of biology, in particular to an African swine fever virus antigen peptide combination, an ELISA kit and application, and the antigen peptide combination is composed of a p30 protein antigen peptide, a p54 protein antigen peptide and a p72 protein antigen peptide; results show that a plurality of antigen peptides of p30, p54 and p72 proteins and ASFV antiserum show positive reaction, the antigen peptides p30-10, p54-12 and p72-3 show the strongest reaction to the ASFV antiserum, are selected as coating antigens and have good specificity, and the sensitivity of the antigen peptide ELISA kit is 1: 1600; compared detection of an ASFV antigen peptide ELISA kit and a commercial kit is carried out on 89 clinical serum samples, the positive coincidence rate is 92%, the negative coincidence rate is 82.8%, the total coincidence rate is 87.4%, and the ASFV antigen peptide ELISA kit has a wide clinical application prospect.

Provided are modified cells and cell lines containing extracellular enveloped viruses (EEV), methods of producing serum-resistant EEVs, and programmed EEVs for systemic oncolytic viral therapy. The viruses are high EEV producing viruses that contain genome modifications that alter properties and / or activities of the viruses. The cells and cell lines are modified to encode polypeptides or peptides that are displayed on their membranes, which, when virus is propagated in the cells, encases the virus so that the polypeptides and peptides from the cell membrane are displayed on the virus. The viruses, thus contain modified outer envelopes that display polypeptides and / or peptides encoded by the virus and from the cell membranes. This combination provides viruses whose properties and activities can be programmed by virtue of the cells in which they are produced and viral genome modifications. The viruses can be used for treating cancers or, because the properties of the virus, including tropisms, other diseases, disorders, and conditions involving targeted cells.

The application provides a non-pH-dependent long-acting anti-serum albumin nanobody and application thereof. Specifically, the application provides amino acid sequences of VHH chain framework regions FR and complementarity determining regions CDR of the non-pH-dependent long-acting anti-serum albumin nanobody. The application also provides nucleotide sequences encoding the nanobody. The anti-serum albumin nanobody provided by the application can bind to human, mouse, rat and cynomolgus serum albumin under different pH conditions, and can significantly prolong the half-life of a protein drug, thereby providing a research basis for long-acting protein drug development.

To provide horse antiserum for betacoronavirus, polyclonal antibodies obtained from the serum, monoclonal antibodies originating from horses, human-chimeric antibodies, humanized antibodies, and mixtures comprising a plurality of monoclonal antibodies.SOLUTION: The present invention provides horse antiserum against an immunogenic composition comprising an RBD region of a spike protein (S protein) of betacoronavirus, the antiserum being capable of neutralizing binding between the S protein and angiotensin-converting enzyme 2 (ACE2).SELECTED DRAWING: None